NCT04237831View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics (Drug Levels and Metabolism), Safety, and Tolerability of BMS-986259 in Participants With Various Levels of Kidney Function

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 26, 2020

Primary Completion Date

July 16, 2021

Study Completion Date

July 16, 2021

Conditions
Renal Failure
Interventions
DRUG

BMS-986259

Specified Dose on Specified Days

Trial Locations (3)

32809

Orlando Clinical Research Center, Orlando

33014

Clinical Pharmacology of Miami, Miami

55114

Prism Clinical Research, Saint Paul

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT04237831 - A Study to Evaluate the Pharmacokinetics (Drug Levels and Metabolism), Safety, and Tolerability of BMS-986259 in Participants With Various Levels of Kidney Function | Biotech Hunter | Biotech Hunter